Jazz Pharmaceuticals plc (JAZZ)
Largest Insider Buys in Sector
JAZZ Stock Price History Chart
JAZZ Stock Performance
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in …
Insider Activity of Jazz Pharmaceuticals plc
Over the last 12 months, insiders at Jazz Pharmaceuticals plc have bought $1.44M and sold $1.97M worth of Jazz Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Jazz Pharmaceuticals plc have bought $3.49M and sold $10.06M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Johnson Philip L (EVP & Chief Financial Officer) — $1.44M.
The last purchase of 12,000 shares for transaction amount of $1.44M was made by Johnson Philip L (EVP & Chief Financial Officer) on 2024‑03‑01.
List of Insider Buy and Sell Transactions, Jazz Pharmaceuticals plc
| 2024-12-02 | Sale | Chairman & CEO | 2,000 0.0033% | $121.17 | $242,340 | +0.99% | ||
| 2024-12-02 | Sale | SVP, Chief Accounting Officer | 53 <0.0001% | $122.49 | $6,492 | +0.99% | ||
| 2024-11-08 | Sale | EVP & Chief Legal Officer | 3,700 0.006% | $123.41 | $456,617 | -0.59% | ||
| 2024-11-01 | Sale | Chairman & CEO | 1,000 0.0016% | $110.84 | $110,840 | +11.10% | ||
| 2024-09-06 | Sale | SVP, Technical Operations | 1,410 0.0023% | $108.30 | $152,703 | +6.99% | ||
| 2024-06-07 | Sale | SVP, Chief Accounting Officer | 163 0.0003% | $108.83 | $17,738 | -0.12% | ||
| 2024-05-03 | Sale | EVP & Chief Legal Officer | 5,000 0.008% | $109.65 | $548,250 | +1.08% | ||
| 2024-03-07 | Sale | SVP, Chief Accounting Officer | 1,768 0.0028% | $116.98 | $206,821 | -4.14% | ||
| 2024-03-06 | Sale | SVP, Chief Accounting Officer | 1,936 0.0032% | $119.64 | $231,628 | -4.85% | ||
| 2024-03-01 | EVP & Chief Financial Officer | 12,000 0.0192% | $119.65 | $1.44M | -6.05% | |||
| 2023-12-04 | Sale | director | 417 0.0007% | $119.27 | $49,736 | -5.52% | ||
| 2023-12-04 | Sale | director | 417 0.0007% | $119.27 | $49,736 | -5.52% | ||
| 2023-09-01 | Sale | EVP & Chief Legal Officer | 1,500 0.0024% | $144.25 | $216,375 | -16.30% | ||
| 2023-08-29 | Sale | SVP, Chief Accounting Officer | 142 0.0002% | $143.47 | $20,373 | -16.22% | ||
| 2023-08-15 | Sale | EVP & Chief Legal Officer | 750 0.0012% | $139.59 | $104,695 | -13.50% | ||
| 2023-08-14 | Sale | director | 1,241 0.0019% | $138.16 | $171,455 | -13.48% | ||
| 2023-08-14 | Sale | director | 1,241 0.0019% | $138.16 | $171,455 | -13.48% | ||
| 2023-08-14 | Sale | director | 1,344 0.0021% | $138.16 | $185,685 | -13.48% | ||
| 2023-08-14 | Sale | director | 1,241 0.0019% | $138.16 | $171,455 | -13.48% | ||
| 2023-08-14 | Sale | director | 1,241 0.0019% | $138.16 | $171,455 | -13.48% |
Insider Historical Profitability
| COZADD BRUCE C | Chairman & CEO | 427025 0.7064% | $122.97 | 1 | 102 | +194.39% |
| Johnson Philip L | EVP & Chief Financial Officer | 27932 0.0462% | $122.97 | 1 | 0 | |
| MICHELSON MICHAEL W | director | 9906501 16.3867% | $122.97 | 1 | 0 | <0.0001% |
| RAETHER PAUL E | 9906501 16.3867% | $122.97 | 1 | 0 | <0.0001% | |
| KKR JP LLC | 9906501 16.3867% | $122.97 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $851.36M | 11.21 | 7.07M | +0.2% | +$1.67M | 0.02 | |
| The Vanguard Group | $776.55M | 10.23 | 6.45M | +1.33% | +$10.23M | 0.01 | |
| State Street | $296.49M | 3.9 | 2.46M | +1.69% | +$4.94M | 0.01 | |
| LSV Asset Management | $286.7M | 3.78 | 2.38M | +1.61% | +$4.53M | 0.6 | |
| JPMorgan Chase | $179.97M | 2.37 | 1.49M | +6.96% | +$11.71M | 0.02 |